Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: Final analysis of an intergroup trial

Cancer

Volumn 97, Issue 8, 2003, Pages 1869-1875

  Hinton, Stuart ^a   Catalano, Paul J ^b   Einhorn, Lawrence H ^a   Nichols, Craig R ^a   Crawford, E David ^c   Vogelzang, Nicholas ^d,e   Trump, Donald ^f   Loehrer, Patrick J ^a,g  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d WEISS MEMORIAL HOSPITAL   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g Indiana Cancer Pavilion   (United States)

Author keywords

BEP (bleomycin, etoposide, cisplatin); Germ cell tumors; International Germ Cell Cancer Collaborative Group; Toxicity; VIP (etoposide, ifosfamide, cisplatin)

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADVANCED CANCER; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; FOLLOW UP; GERM CELL TUMOR; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; NAUSEA; NEUROLOGIC DISEASE; PATIENT CODING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; ETOPOSIDE; FOLLOW-UP STUDIES; GERMINOMA; HUMANS; IFOSFAMIDE; MALE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0344806946     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11271     Document Type: Article

References (22)

1. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990;8:1777-1781.
2. Bosl GJ, Geller NL, Cirrincione C, et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res. 1983;43:3403-3407.
3. Birch R, Williams S, Cone A, et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol. 1986;4:400-407.
4. Stoter G, Sylvester R, Sleijfer DT, et al. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multi-institutional Phase III Study. Cancer Res. 1987;47:2714-2718.
5. Droz JP, Kramar A, Ghosn M, et al. Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis. Cancer. 1988;62:564-568.
6. Mead GM, Stenning SP, Parkinson MC, et al. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol. 1992;10:85-94.
7. International Germ Cell Consensus Classification. A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15:594-603.
8. Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol. 1998;16:1287-1293.
9. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
11. Baniel J, Foster RS, Gonin R, et al. Late relapse of testicular cancer. J Clin Oncol. 1995;13:1170-1176.
12. Nichols CR, Roth BJ, Heerema N, et al. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med. 1990;322:1425-1429.
13. Nichols CR, Breeden ES, Loehrer PJ, et al. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst. 1993;85:36-40.
14. Bredeson CN, Barnett MJ, Horsman DE, et al. Therapyrelated acute myelogenous leukemia associated with 11q23 chromosomal abnormalities and topoisomerase II inhibitors: report of four additional cases and brief commentary. Leuk Lymphoma. 1993;11:141-145.
15. Fong CT, Brodeur GM. Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet Cytogenet. 1987;28:55-76.
16. Einhorn LH, Williams SD, Troner M, et al. The role of maintenance therapy in disseminated testicular cancer. N Engl J Med. 1981;305:727-731.
17. Stoter G, Sleyfer DT, ten Bokkel Huinink WW, et al. High-dose versus low-dose vinblastine in cisplatin-vinblastinebleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1986;4:1199-1206.
18. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316:1435-1440.
19. Culine S, Kerbrat P, Bouzy J, et al. Are 3 cycles of bleomycin, etoposide and cisplatin (3bep) or 4 cycles of etoposide and cisplatin (4ep) equivalent regimens for patients (pts) with good-risk metastatic non seminomatous germ cell tumors (NSGCT)? Preliminary results of a randomized trial [abstract]. Proc Am Soc Clin Oncol. 1999;18:309a.
20. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol. 1989;7:387-391.
21. Loehrer PJ, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995;13:470-476.
22. Kollmannsberger C, Nichols C, Meisner C, et al. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol. 2000;11:1115-1120.